BMO Downgrades Gilead Sciences (GILD) to Market Perform
More News related to GILD
- Gilead Sciences to Present at the 18th Annual Credit Suisse Healthcare Conference on Wednesday, November 11
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Gilead Sciences (GILD) and Glaxo (GSK) Announce Pulmonary Arterial Hypertension Clinical Trial
- Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
- Gilead Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating Viread(R) For Chronic Hepatitis B
More News related to Downgrades
- RBC Capital Downgrades JA Solar (JASO) to Sector Perform
- Morgan Keegan Downgrades Zions Bancorporation (ZION) to Market Perform
- Hilliard Lyons Downgrades Humana (HUM) to Neutral
- Credit Suisse Downgrades Priceline.com (PCLN) to Neutral
- Citi Downgrades Allegheny Energy (AYE) to Hold
BMO Capital downgrades Gilead Sciences (Nasdaq: GILD) from Outperform to Market Perform.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases.
Related Categories
DowngradesStocks Mentioned
+0.44Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
